Vincenzo Libri is a Clinical Senior Lecturer within the Division of Investigative Science at Imperial College London and Head of Clinical Studies at the ‘Sir John McMichael’ Clinical Research Centre - Hammersmith Campus. He also coordinates a MRes in Translational Medicine for graduates in medicine and basic scientists with a degree in life sciences.
From 1990 to 1998 he was a Welcome Trust and Medical Research Council Grant Holder at the School of Pharmacy, University of London (UK). In 1994 he was appointed Lecturer in Clinical Pharmacology at the University of Rome, (Italy). In the last ten years, Vincenzo has worked in multiple Pharmaceutical Companies (GlaxoWellcome, Eli Lilly, and GlaxoSmithKline) undertaking direct responsibilities for phase I/II clinical trials. In 2004 he was appointed Head of Experimental and Translational Medicine at the Department of Clinical Pharmacology and Discovery Medicine, Neurology CEDD, GSK-UK.
Dr Libri joined Imperial College in April 2009 to lead a team of clinicians, nurses and administrative staff and coordinate the development of a sustainable portfolio of clinical trials and experimental medicine studies across therapeutic areas. He is a Principal Investigator for the development and implementation of Phase I/II clinical trials in healthy volunteers and patients, with primary interests in experimental neurology, translational medicine and clinical neuro-pharmacology.
et al., 2023, COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2., Eclinicalmedicine, Vol:56, ISSN:2589-5370, Pages:1-13
et al., 2022, Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial, The Lancet Respiratory Medicine, Vol:10, ISSN:2213-2600, Pages:1049-1060
et al., 2022, Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial, Lancet Infectious Diseases, Vol:22, ISSN:1473-3099, Pages:1131-1141
et al., 2022, Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial, Journal of Infection, Vol:84, ISSN:0163-4453, Pages:795-813
et al., 2022, Impact of priming interval on reactogenicity, peak immunological response and waning after homologous and heterologous COVID-19 vaccine schedules: Exploratory analyses of Com-COV, a randomised control trial, The Lancet Respiratory Medicine, ISSN:2213-2600